Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion

Molecular Cancer Research

Volumn 6, Issue 10, 2008, Pages 1534-1543

  Ilvesaro, Joanna M ^a   Merrell, Melinda A ^a   Li, Li ^a   Wakchoure, Savita ^a   Graves, David ^b   Brooks, Sonja ^b   Rahko, Eeva ^d   Jukkola Vuorinen, Arja ^d   Vuopala, Katri S ^e   Harris, Kevin W ^a,c   Selander, Katri S ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c BIRMINGHAM VA MEDICAL CENTER   (United States)

^d OULU UNIVERSITY HOSPITAL   (Finland)

^e LAPLAND CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; CPG OLIGODEOXYNUCLEOTIDE; DOUBLE STRANDED DNA; MYELOID DIFFERENTIATION FACTOR 88; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CELL INVASION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MACROPHAGE; METHYLATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECONDARY STRUCTURE;

ANIMALS; BASE SEQUENCE; BREAST NEOPLASMS; DNA METHYLATION; FEMALE; GENES, DOMINANT; HUMANS; MICE; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; NUCLEIC ACID CONFORMATION; NUCLEIC ACID HETERODUPLEXES; OLIGODEOXYRIBONUCLEOTIDES; TNF RECEPTOR-ASSOCIATED FACTOR 6; TOLL-LIKE RECEPTOR 9;

MUS; VERTEBRATA;

EID: 54249157845     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-07-2005     Document Type: Article

References (48)

1. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003;85:85-95.
2. Wagner H. The immunobiology of the TLR9 subfamily. Trends Immunol 2004;25:381-6.
3. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-5.
4. Lee S, Hong J, Choi SY, et al. CpG oligodeoxynucleotides induce expression of proinflammatory cytokines and chemokines in astrocytes: the role of c-Jun N-terminal kinase in CpG ODN-mediated NF-κB activation. J Neuroimmunol 2004;153:50-63.
5. Latz E, Visintin A, Espevik T, Golenbock DT. Mechanisms of TLR9 activation. J Endotoxin Res 2004;10:406-12.
6. Takeshita F, Gursel I, Ishii KJ, Suzuki K, Gursel M, Klinman DM. Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. Semin Immunol 2004;16:17-22.
7. Tsan MF, Gao B. Endogenous ligands of Toll-like receptors. J Leukoc Biol 2004;76:514-9.
8. Marshak-Rothstein A, Rifkin IR. Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. Annu Rev Immunol 2007;25:419-41.
9. Matsumoto M, Funami K, Tanabe M, et al. Subcellular localization of Toll-like receptor 3 in human dendritic cells. J Immunol 2003;171:3154-62.
10. Nishiya T, DeFranco AL. Ligand-regulated chimeric receptor approach reveals distinctive subcellular localization and signaling properties of the Toll-like receptors. J Biol Chem 2004;279:19008-17.
11. Schmausser B, Andrulis M, Endrich S, et al. Expression and subcellular distribution of toll-like receptors TLR4, TLR5 and TLR9 on the gastric epithelium in Helicobacter pylori infection. Clin Exp Immunol 2004;136:521-6.
12. Leifer CA, Kennedy MN, Mazzoni A, Lee C, Kruhlak MJ, Segal DM. TLR9 is localized in the endoplasmic reticulum prior to stimulation. J Immunol 2004;173:1179-83.
13. Latz E, Schoenemeyer A, Visintin A, et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004;5:190-8.
14. Kaisho T, Akira S. Toll-like receptor function and signaling. J Allergy Clin Immunol 2006;117:979-87; quiz 988.
15. Ilvesaro JM, Merrell MA, Swain TM, et al. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate 2007;67:774-81.
16. Schaefer TM, Desouza K, Fahey JV, Beagley KW, Wira CR. Toll-like receptor (TLR) expression and TLR-mediated cytokine/chemokine production by human uterine epithelial cells. Immunology 2004;112:428-36.
17. Bowman CC, Rasley A, Tranguch SL, Marriott I. Cultured astrocytes express toll-like receptors for bacterial products. Glia 2003;43:281-91.
18. Platz J, Beisswenger C, Dalpke A, et al. Microbial DNA induces a host defense reaction of human respiratory epithelial cells. J Immunol 2004;173:1219-23.
19. Mempel M, Voelcker V, Kollisch G, et al. Toll-like receptor expression in human keratinocytes: nuclear factor κB controlled gene activation by Staphylococcus aureus is toll-like receptor 2 but not toll-like receptor 4 or platelet activating factor receptor dependent. J Invest Dermatol 2003;121:1389-96.
20. Schmausser B, Andrulis M, Endrich S, Muller-Hermelink HK, Eck M. Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol 2005;295:179-85.
21. Droemann D, Albrecht D, Gerdes J, et al. Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res 2005;6:1.
22. Merrell MA, Ilvesaro JM, Lehtonen N, et al. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res 2006;4:437-47.
23. Dorn A, Ludwig RJ, Bock A, et al. Oligonucleotides suppress IL-8 in skin keratinocytes in vitro and offer anti-inflammatory properties in vivo. J Invest Dermatol 2007;127:846-54.
24. Cortez-Gonzalez X, Pellicciotta I, Gerloni M, et al. TLR9-independent activation of B lymphocytes by bacterial DNA. DNA Cell Biol 2006;25:253-61.
25. Yeo SJ, Yoon JG, Yi AK. Myeloid differentiation factor 88-dependent posttranscriptional regulation of cyclooxygenase-2exp ression by CpG DNA: tumor necrosis factor-α receptor-associated factor 6, a diverging point in the Toll-like receptor 9-signaling. J Biol Chem 2003;278:40590-600.
26. Merrell M, Suarez-Cuervo C, Harris KW, Vaananen HK, Selander KS. Bisphosphonate induced growth inhibition of breast cancer cells is augmented by p38 inhibition. Breast Cancer Res Treat 2003;81:231-41.
27. Takeshita F, Leifer CA, Gursel I, et al. Cutting edge: role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol 2001;167:3555-8.
28. Wu CC, Lee J, Raz E, Corr M, Carson DA. Necessity of oligonucleotide aggregation for toll-like receptor 9 activation. J Biol Chem 2004;279:33071-8.
29. Shimosato T, Kimura T, Tohno M, et al. Strong immunostimulatory activity of AT-oligodeoxynucleotide requires a six-base loop with a self-stabilized 5′-C. . .G-3′ stem structure. Cell Microbiol 2006;8:485-95.
30. Trevani AS, Chorny A, Salamone G, et al. Bacterial DNA activates human neutrophils by a CpG-independent pathway. Eur J Immunol 2003;33:3164-74.
31. Wagner H, Bauer S. All is not Toll: new pathways in DNA recognition. J Exp Med 2006;203:265-8.
32. Lim EJ, Lee SH, Lee JG, et al. Activation of toll-like receptor-9 induces matrix metalloproteinase-9 expression through Akt and tumor necrosis factor-α signaling. FEBS Lett 2006;580:4533-8.
33. Miyahara T, Koyama H, Miyata T, et al. Inflammatory signaling pathway containing TRAF6 contributes to neointimal formation via diverse mechanisms. Cardiovasc Res 2004;64:154-64.
34. Sanjuan MA, Rao N, Lai KT, et al. CpG-induced tyrosine phosphorylation occurs via a TLR9-independent mechanism and is required for cytokine secretion. J Cell Biol 2006;172:1057-68.
35. Lee JW, Choi JJ, Seo ES, et al. Increased toll-like receptor 9 expression in cervical neoplasia. Mol Carcinog 2007;46:941-7.
36. Anderson KV, Jurgens G, Nusslein-Volhard C. Establishment of dorsalventral polarity in the Drosophila embryo: genetic studies on the role of the Toll gene product. Cell 1985;42:779-89.
37. Kelleher FC, Fennelly D, Rafferty M. Common critical pathways in embryogenesis and cancer. Acta Oncol 2006;45:375-88.
38. Rao VP, Poutahidis T, Ge Z, et al. Innate immune inflammatory response against enteric bacteria Helicobacter hepaticus induces mammary adenocarcinoma in mice. Cancer Res 2006;66:7395-400.
39. Rao VP, Poutahidis T, Fox JG, Erdman SE. Breast cancer: should gastrointestinal bacteria be on our radar screen? Cancer Res 2007;67:847-50.
40. Katz J, Zhang P, Martin M, Vogel SN, Michalek SM. Toll-like receptor 2 is required for inflammatory responses to Francisella tularensis LVS. Infect Immun 2006;74:2809-16.
41. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002;296:550-3.
42. Yin JJ, Selander K, Chirgwin JM, et al. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999;103:197-206.
43. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 2003;31:3406-15.
44. Jukkola-Vuorinen A, Rahko E, Vuopala KS, et al. Toll-like receptor-9 expression is inversely correlated with estrogen receptor status in breast cancer. J Innate Immun 2009;1:59-68 (DOI:10.1159/000151602).
45. Chhieng DC, Frost AR, Niwas S, Weiss H, Grizzle WE, Beeken S. Intratumor heterogeneity of biomarker expression in breast carcinomas. Biotech Histochem 2004;79:25-36.
46. Frost AR, Sparks D, Grizzle WE. Methods of antigen recovery vary in their usefulness in unmasking specific antigens in immunohistochemistry. Appl Immunohistochem Mol Morphol 2000;8:236-43.
47. Talley LI, Grizzle WE, Waterbor JW, Brown D, Weiss H, Frost AR. Hormone receptors and proliferation in breast carcinomas of equivalent histologic grades in pre- and postmenopausal women. Int J Cancer 2002;98:118-27.
48. Selander KS, Monkkonen J, Karhukorpi EK, Harkonen P, Hannuniemi R, Vaananen HK. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 1996;50:1127-38.